Categories: BioTechDrugFutureHealthTechPlanning
Kynexis is a precision neuropsychiatry company based in The Netherlands that is built on two key concepts: best-in-class molecules and precision medicine. Kynexis' lead candidate, KYN-5356, a potent KAT-II inhibitor is designed to regulate kynurenic acid levels in the brains of patients with cognitive impairment, associated with schizophrenia (CIAS). The precision angle of the program relates to a genetic link of this mechanism with the disease, combined with a clinical patient selection strategy. Applying this precision medicine concept, the company is planning to expand its pipeline and indication scope beyond CIAS in the future.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.11.2023 | Series A | $61M | - |
Mentions in press and media 2
Reviews 0
